Literature DB >> 21314797

Grassroots marketing in a global era: more lessons from BiDil.

Britt M Rusert1, Charmaine D M Royal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21314797      PMCID： PMC3172009          DOI： 10.1111/j.1748-720X.2011.00552.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN： 1073-1105            Impact factor:   1.718


× No keyword cloud information.
  17 in total

1.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Authors:  Anne L Taylor; Susan Ziesche; Clyde Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood Adams; Michael Sabolinski; Manuel Worcel; Jay N Cohn
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

2.  Race, pharmacogenomics, and marketing: putting BiDil in context.

Authors:  Jonathan Kahn
Journal:  Am J Bioeth       Date:  2006 Sep-Oct       Impact factor: 11.229

3.  Race-based medicine and justice as recognition: exploring the phenomenon of BiDil.

Authors:  Joon-Ho Yu; Sara Goering; Stephanie M Fullerton
Journal:  Camb Q Healthc Ethics       Date:  2009       Impact factor: 1.284

4.  Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients.

Authors:  George T H Ellison; Jay S Kaufman; Rosemary F Head; Paul A Martin; Jonathan D Kahn
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

5.  Understanding race at the frontier of pharmaceutical regulation: an analysis of the racial difference debate at the ICH.

Authors:  Wen-Hua Kuo
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

6.  Popular representations of race: the news coverage of BiDil.

Authors:  Timothy Caulfield; Simrat Harry
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

7.  Introduction: Facts and fictions: BiDil and the resurgence of racial medicine.

Authors:  Gregory Michael Dorr; David S Jones
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

8.  "Special treatment": BiDil, Tuskegee, and the logic of race.

Authors:  Susan M Reverby
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

9.  "A study in nature": the Tuskegee experiments and the New South plantation.

Authors:  Britt Rusert
Journal:  J Med Humanit       Date:  2009-09

10.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.

Authors:  P Carson; S Ziesche; G Johnson; J N Cohn
Journal:  J Card Fail       Date:  1999-09       Impact factor: 5.712
View more
  3 in total

Review 1.  Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards.

Authors:  Hojjat Soofi; Evert van Leeuwen
Journal:  J Community Genet       Date:  2016-08-05

2.  Advancing genomic research and reducing health disparities: what can nurse scholars do?

Authors:  Cheedy Jaja; Robert Gibson; Shirley Quarles
Journal:  J Nurs Scholarsh       Date:  2013-03-01       Impact factor: 3.176

3.  BiDil in the Clinic: An Interdisciplinary Investigation of Physicians' Prescription Patterns of a Race-Based Therapy.

Authors:  Koffi N Maglo; Jack Rubinstein; Bin Huang; Richard F Ittenbach
Journal:  AJOB Empir Bioeth       Date:  2014-10-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.